News

FDA issued a decision holding that eligibility for 180 days of exclusivity is only available to an applicant who first filed a PIV certification to an original patent

The center will be located near the Research Triangle Park in Cary, North Carolina where the company will invest $36 million over the next three years and create

As part of the settlement, Neptune granted a world-wide, non-exclusive, royalty-bearing license to Enzymotec, allowing it to market and sell its nutraceutical products under Neptune’s ‘348 family of

Takeda applied for this subsidy in February to expand production capacity for pandemic influenza vaccines at its Hikari Plant (Hikari City, Yamaguchi Prefecture). In return for the subsidy,

The CHMP positive opinion follows recent US FDA approval of the drug for treatment of and reduction in the risk of recurrent DVT and PE. Both DVT and

The patent, which is the company’s first specifically targeting neurological conditions, is granted for the US market and is valid until 2022. The company said that the claims

The multicenter, double-blind, randomized, controlled Phase IIIb trial compares a single dose of Dalvance with the once-weekly dosage regimen of Dalvance in adult patients with ABSSSI. In the

Recently, a double-blind, placebo-controlled, multicenter Phase II trial of three doses of GED-0301 in 166 patients with active Crohn’s disease has been completed. Based on the data, which

Under the deal, Agendia’s oncology biomarker technology will be used in the evaluation of new pharmaceuticals now being researched in certain Daiichi Sankyo clinical trials. Agendia president and